614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients

Routy, Bertrand; Lenehan, John; Daisley, Brendan A.; Messaoudene, Meriem; Al, Kait F.; Richard, Corentin; Miller, Wilson H.; Jamal, Rahima; Ernst, Scott; Logan, Diane; Bélanger, Karl; Gili, Luara Martinez-; Mullish, Benjamin H.; Takis, Panteleimon G.; Samayoa, Cecilia Hermosilla; Ninkov, Marina; Parvathy, Seema Nair; Lambert, Caroline; Elkrief, Arielle; Lapointe, Réjean; Haeryfar, Mansour; Burton, Jeremy P.; Silverman, Michael E.; Maleki, Saman

doi:10.1136/jitc-2022-sitc2022.0614

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Firstly, studies have shown that FMT has a certain auxiliary effect on tumor immunotherapy (27,54,92). However, the potential risks of disease transmission between donors and recipients, patient acceptance, undesirable outcomes, and uncertainties regarding effects on the immune system of recipients underscore the critical need for large-sample randomized controlled studies to comprehensively assess the effectiveness of FMT (93, 94).…”

Section: Discussionmentioning

confidence: 99%

Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer

Xin,

Liu,

Zang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

Non–small cell lung cancer (NSCLC) accounts for 80–85% of all lung cancers. In recent years, treatment with immune checkpoint inhibitors (ICIs) has gradually improved the survival rate of patients with NSCLC, especially those in the advanced stages. ICIs can block the tolerance pathways that are overexpressed by tumor cells and maintain the protective activity of immune system components against cancer cells. Emerging clinical evidence suggests that gut microbiota may modulate responses to ICIs treatment, possibly holding a key role in tumor immune surveillance and the efficacy of ICIs. Studies have also shown that diet can influence the abundance of gut microbiota in humans, therefore, dietary interventions and the adjustment of the gut microbiota is a novel and promising treatment strategy for adjunctive cancer therapy. This review comprehensively summarizes the effects of gut microbiota, antibiotics (ATBs), and dietary intervention on the efficacy of immunotherapy in NSCLC, with the aim of informing the development of novel strategies in NSCLC immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer

Xin,

Liu,

Zang

et al. 2024

Front. Immunol.

View full text Add to dashboard Cite

show abstract

“…Microbiota composition is related to ICIs sensitivity. Combining anti-PD-1 with fecal microbiota transplantation (FMT) from healthy donors could enhance sensitivity to anti-PD-1 treatment ( 184 ). The antibiotic application which could change microbiota composition may impair the efficacy of ipilimumab.…”

Section: Drug Resistance Mechanismmentioning

confidence: 99%

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer

Zhou

Zhao

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Immune checkpoint inhibitors (ICIs) in the form of anti-CTLA-4 and anti-PD-1/PD-L1 have become the frontier of cancer treatment and successfully prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC). But the efficacy varies among different patient population, and many patients succumb to disease progression after an initial response to ICIs. Current research highlights the heterogeneity of resistance mechanisms and the critical role of tumor microenvironment (TME) in ICIs resistance. In this review, we discussed the mechanisms of ICIs resistance in NSCLC, and proposed strategies to overcome resistance.

show abstract

614 Microbiome modification with fecal microbiota transplant from healthy donors before anti-PD1 therapy reduces primary resistance to immunotherapy in advanced and metastatic melanoma patients

Cited by 2 publications

References 0 publications

Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer

Gut microbiota and dietary intervention: affecting immunotherapy efficacy in non–small cell lung cancer

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer

Contact Info

Product

Resources

About